Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 in Advanced Solid Tumors or Lymphoma
NCT03692520Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sct200 in solid tumor (advanced stage), lymphoma, gastric cancer (GC) and 7 more, sponsored by Sinocelltech Group Limited. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
sct200
03
Conditions
solid tumor (advanced stage)lymphomagastric cancer (GC)gastroesophageal junction cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03692520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692520.